blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3816182

EP3816182 - LIGAND-BINDING MOLECULE CONTAINING SINGLE DOMAIN ANTIBODY [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  03.04.2021
Database last updated on 12.07.2024
FormerThe international publication has been made
Status updated on  07.12.2019
Most recent event   Tooltip28.05.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
CHUGAI SEIYAKU KABUSHIKI KAISHA
5-1, 5-chome Ukima
Kita-ku
Tokyo 115-8543 / JP
[2021/18]
Inventor(s)01 / ISHIKAWA, Hiroyuki
c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 135,
Komakado 1-chome
Gotemba-shi, Shizuoka 412-8513 / JP
02 / KAWA, Tatsuya
c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 135,
Komakado 1-chome
Gotemba-shi, Shizuoka 412-8513 / JP
03 / HIRONIWA, Naoka
c/o Chugai Pharmabody Research Pte. Ltd., 3,
Biopolis Drive, 07-11 to 16
Synapse, 138623 / SG
 [2021/18]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2021/18]
Application number, filing date19810410.130.05.2019
[2021/18]
WO2019JP21464
Priority number, dateJP2018010370130.05.2018         Original published format: JP 2018103701
[2021/18]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019230868
Date:05.12.2019
Language:JA
[2019/49]
Type: A1 Application with search report 
No.:EP3816182
Date:05.05.2021
Language:EN
[2021/18]
Search report(s)International search report - published on:JP05.12.2019
(Supplementary) European search report - dispatched on:EP10.06.2022
ClassificationIPC:C07K16/00, A61K39/395, C07K19/00
[2021/18]
CPC:
C07K16/2866 (EP,US); C07K16/00 (US); A61K47/6813 (US);
A61K47/6845 (US); C07K14/70521 (US); C07K14/7155 (US);
C07K16/2818 (EP,US); C07K19/00 (EP); C07K2317/53 (EP);
C07K2317/569 (EP,US); C07K2317/64 (EP); C07K2317/76 (US);
C07K2317/94 (EP); C07K2319/32 (EP,US); C07K2319/33 (US);
C07K2319/50 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/18]
TitleGerman:LIGANDBINDUNGSMOLEKÜL MIT EINZELDOMÄNEN-ANTIKÖRPER[2021/18]
English:LIGAND-BINDING MOLECULE CONTAINING SINGLE DOMAIN ANTIBODY[2021/18]
French:MOLÉCULE DE LIAISON À UN LIGAND CONTENANT UN ANTICORPS À DOMAINE UNIQUE[2021/18]
Entry into regional phase03.12.2020Translation filed 
03.12.2020National basic fee paid 
03.12.2020Search fee paid 
03.12.2020Designation fee(s) paid 
03.12.2020Examination fee paid 
Examination procedure03.12.2020Examination requested  [2021/18]
29.12.2022Amendment by applicant (claims and/or description)
Fees paidRenewal fee
21.05.2021Renewal fee patent year 03
25.03.2022Renewal fee patent year 04
23.03.2023Renewal fee patent year 05
27.05.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]WO2004021861  (LAUERMANN VIT [US]) [X] 1-10,13-15 * page 2, line last 6 - page 3, line first 2 * * page 3, lines 14,17 * * page 4, lines 17-18 * * example 2; claim - * [I] 11,12;
 [XI]WO2011123683  (UNIV ROCHESTER [US], et al) [X] 1-10,13-15 * pages 25,31; figure 5A; example 5 * [I] 11,12;
 [XP]WO2018097308  (CHUGAI PHARMACEUTICAL CO LTD [JP]) [XP] 1-15 * abstract *;
 [E]WO2019107384  (CHUGAI PHARMACEUTICAL CO LTD [JP]) [E] 1-15 * abstract *;
 EP3546480  [ ] (CHUGAI PHARMACEUTICAL CO LTD [JP]) [ ] * the whole document *;
 EP3719036  [ ] (CHUGAI PHARMACEUTICAL CO LTD [JP]) [ ] * the whole document *
International search[A]JP2011026298  (CANON KK) [A] 1-15 * & US 2011/0064666 A1 *;
 [A]JP2013538204  (ROCHE GLYCART AG.) [A] 1-15 * & US 2013/0266568 A1 & EP 2609112 A1 & CN 103068847 A & KR 10-2013-0041963 A *;
 [A]JP2014509605  (THE UNIVERSITY OF BIRMINGHAM) [A] 1-15* & US 2014/0004081 A1 & WO 2012/123755 A1 & EP 2686020 A1 & CN 103561771 A *;
 [A]JP2015509952  (THE UNIVERSITY OF BIRMINGHAM) [A] 1-15 * & US 2015/0183875 A1 & WO 2013/128194 A1 & EP 2819701 A1 & CN 104321081 A *;
 [A]JP2015517320  (LIFE TECHNOLOGIES AS) [A] 1-15 * & US 2015/0175698 A1 & WO 2013/176730 A1 & EP 2852617 A1 *;
 [A]WO2016182064  (CHUGAI PHARMACEUTICAL CO LTD [JP]) [A] 1-15 * & US 2018/0125972 A1 & EP 3296395 A1 *;
 [A]WO2017025698  (UNIV LONDON QUEEN MARY [GB]) [A] 1-15 * (Family: none) *;
 [A]JP2017529853  (AMGEN INC.) [A] 1-15 * & US 2017/0247476 A1 & WO 2016/046778 A2 & EP 3197916 A2 *;
 [PX]WO2018097308  (CHUGAI PHARMACEUTICAL CO LTD [JP]) [PX] 1-15 * , claims, fig. 1-31 & CA 3039316 A1 & AU 2017364818 A1 claims *;
 [A]  - PUSKAS, JOHN et al., "Development of an attenuated interleukin-2 fusion protein that can be activated by tumor-expressed proteases", Immunology, (20110000), vol. 133, no. 2, doi:10.1111/j.1365-2567.2011.03428.x, pages 206 - 220, XP055073392 [A] 1-15

DOI:   http://dx.doi.org/10.1111/j.1365-2567.2011.03428.x
by applicantUS4816567
 US6248516
 WO03000883
 WO03104453
 WO2004022754
 WO2006006693
 WO2009025846
 WO2009125825
 WO2010081173
 US2011123527
 WO2013128194
 WO2015048329
 WO2015116933
 WO2015143414
 WO2016014974
 WO2016046778
 WO2016118629
 US2016289324
 US2016311903
 WO2016179257
 WO2016179285
 WO2016179335
 WO2016179003
    - JANICE M REICHERTCLARK J ROSENSWEIGLAURA B FADENMATTHEW C DEWITZ, "Monoclonal antibody successes in the clinic", Nat. Biotechnol., (20050000), vol. 23, doi:10.1038/nbt0905-1073, pages 1073 - 1078, XP002555770

DOI:   http://dx.doi.org/10.1038/nbt0905-1073
    - PAVLOU AKBELSEY MJ., "The therapeutic antibodies market to 2008", Eur. J. Pharm. Biopharm., (20050000), vol. 59, no. 3, doi:10.1016/j.ejpb.2004.11.007, pages 389 - 396, XP025317626

DOI:   http://dx.doi.org/10.1016/j.ejpb.2004.11.007
    - WEINER LMSURANA RWANG S., "Monoclonal antibodies: versatile platforms for cancer immunotherapy", Nat. Rev. Immunol., (20100000), vol. 10, no. 5, doi:10.1038/nri2744, pages 317 - 327, XP055217481

DOI:   http://dx.doi.org/10.1038/nri2744
    - GLADKOV ORAMLAU RSERWATOWSKI PMILANOWSKI JTOMECZKO JKOMARNITSKY PBKRAMER DKRZAKOWSKI MJ, "Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer", Anticancer Drugs, (20151100), vol. 26, no. 10, pages 1061 - 8
    - PAOLONI MMAZCKO CSELTING KLANA SBARBER LPHILLIPS JSKORUPSKI KVAIL DWILSON HBILLER B, "Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma", PLoS One, (20150619), vol. 10, no. 6, page e0129954
    - PAPADIA FBASSO VPATUZZO RMAURICHI ADI FLORIO AZARDI LVENTURA EGONZALEZ-IGLESIAS RLOVATO VGIOVANNONI L, "Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma", J Surg Oncol, (20130200), vol. 107, no. 2, doi:10.1002/jso.23168, pages 173 - 9, XP055413902

DOI:   http://dx.doi.org/10.1002/jso.23168
    - TZENG AKWAN BHOPEL CFNAVARATNA TWITTRUP KD, "Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution", Proc Natl Acad Sci U S A, (20150317), vol. 112, no. 11, pages 3320 - 5, XP002779698
    - KUNKEL et al., Proc. Natl. Acad. Sci. USA, (19850000), vol. 82, pages 488 - 492
    - Annu. Rev. Biophys. Biomol. Struct., (20060000), vol. 35, pages 225 - 249
    - Proc. Natl. Acad. Sci. U.S.A., (20030000), vol. 100, no. 11, pages 6353 - 6357
    - FLATMAN et al., J. Chromatogr. B, (20070000), vol. 848, pages 79 - 87
    - CHOTHIALESK, J. Mol. Biol., (19870000), vol. 196, pages 901 - 917
    - CLACKSON et al., Nature, (19910000), vol. 352, pages 624 - 3242
    - MACCALLUM et al., J. Mol. Biol., (19960000), vol. 262, pages 732 - 745
    - Methods in Molecular Biology, (20120000), vol. 911, pages 65 - 78
    - Biochimica et Biophysica Acta - Proteins and Proteomics, (20060000), vol. 1764, no. 8, pages 1307 - 1319
    - Journal of Applied Microbiology, (20140000), vol. 117, no. 2, pages 528 - 536
    - Journal of Biomolecular Screening, (20160000), vol. 21, no. 1, pages 35 - 43
    - Journal of Biological Chemistry, (20160000), vol. 291, no. 24, pages 12641 - 12657
    - AIDS, (20160000), vol. 30, no. 11, pages 1691 - 1701
    - C VINCKE et al., The Journal of Biological Chemistry, vol. 284, pages 3273 - 3284
    - J Inflamm (Lond, (20100000), vol. 7, page 45
    - Nat Rev Immunol, (20060700), vol. 6, no. 7, pages 541 - 50
    - Nat Rev Drug Discov, (20141200), vol. 13, no. 12, pages 904 - 27
    - Respir Res, (20160304), vol. 17, page 23
    - Dis Model Mech, (20140200), vol. 7, no. 2, pages 193 - 203
    - Biochim Biophys Acta, (20120100), vol. 1824, no. 1, pages 133 - 45
    - Nat Rev Cancer, (20030700), vol. 3, no. 7, pages 489 - 501
    - PNAS, (20130102), vol. 110, no. 1, pages 93 - 98
    - Nat Rev Drug Discov, (20100900), vol. 9, no. 9, pages 690 - 701
    - J. Immunol., (19940000), vol. 152, no. 10, pages 4958 - 4968
    - Nucleic Acids Res, (19890000), vol. 17, no. 8, pages 2919 - 2932
    - J. Immunol., (19790000), vol. 123, no. 4, pages 1548 - 1550
    - Current Topics in Microbiology and Immunology, (19780000), vol. 81, pages 1 - 7
    - J. Immunol., (19760000), vol. 6, no. 7, pages 511 - 519
    - Cell, (19760000), vol. 8, no. 3, pages 405 - 415
    - Nature, (19780000), vol. 276, no. 5685, pages 269 - 270
    - J. Immunol. Methods, (19800000), vol. 35, no. 1-2, pages 1 - 21
    - J. Exp. Med., (19780000), vol. 148, no. 1, pages 313 - 323
    - Nature, (19790000), vol. 277, no. 5692, pages 131 - 133
    - KOHLERMILSTEIN et al., Methods Enzymol, (19810000), vol. 73, pages 3 - 46
    - VANDAMME et al., Eur. J. Biochem., (19900000), vol. 192, no. 3, pages 767 - 775
    - Biochemistry, (19790000), vol. 18, no. 24, pages 5294 - 5299
    - Anal. Biochem., (19870000), vol. 162, no. 1, pages 156 - 159
    - Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, no. 23, pages 8998 - 9002
    - Proc. Natl. Acad. Sci. USA, (20060000), vol. 103, no. 11, pages 4005 - 4010
    - Methods Enzymol, (20000000), vol. 323, pages 325 - 40
    - Nature Biotechnology, (20010000), vol. 19, pages 661 - 667
    - PNAS, (20000000), vol. 97, pages 7754 - 7759
    - Biochemical Journal, (20100000), vol. 426, pages 219 - 228
    - BEILSTEIN, J Nanotechnol, (20160000), vol. 7, pages 364 - 373
    - J Biol Chem, (19881015), vol. 263, no. 29, pages 15064 - 70
    - J Clin Invest, (19530800), vol. 32, no. 8, pages 746 - 768
    - Antibodies, (20150000), vol. 4, no. 3, pages 141 - 156
    - J Pharm Sci, (20081000), vol. 97, no. 10, pages 4167 - 83
    - CLARK-LEWIS et al., J. Biol. Chem., (19940000), vol. 269, pages 16075 - 16081
    - BELPERIO et al., "CXC Chemokines in Angiogenesis", J. Leukoc. Biol., (20000000), vol. 68, pages 1 - 8, XP002440747
    - DUFOUR et al., "IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking", J Immunol., (20020000), vol. 168, pages 3195 - 204
    - KIESEIER et al., "Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10", Brain, (20020000), vol. 125, pages 823 - 34
    - NAGASAWA, T., Int. J. Hematol., (20000000), vol. 72, pages 408 - 11
    - GAZITT, Y., J. Hematother Stem Cell Res, (20010000), vol. 10, pages 229 - 36
    - HATTORI et al., Blood, (20010000), vol. 97, pages 3354 - 59
    - NOMURA et al., Int. J. Cancer, (20010000), vol. 91, pages 597 - 606
    - MACHDRANOFF, Curr. Opin. Immunol., (20000000), vol. 12, pages 571 - 75
    - BRUCE, L. et al., "Radiolabeled Chemokine binding assays", Methods in Molecular Biology, (20000000), vol. 138, pages 129 - 134
    - RAPHAELE, B. et al., "Calcium Mobilization", Methods in Molecular Biology, (20000000), vol. 138, pages 143 - 148
    - "Transwell Chemotaxis", PAUL D. PONATH et al., Methods in Molecular Biology, Humana Press, (20000000), vol. 138, pages 113 - 120
    - PLoS One, (20100913), vol. 5, no. 9, page e12700
    - OKAZAKI et al., Curr. Opin. Immunol., (20020000), vol. 14, pages 391779 - 82
    - BENNETT et al., J Immunol, (20030000), vol. 170, pages 711 - 8
    - HUTLOFF et al., Nature, (19990000), vol. 397, pages 263 - 266
    - HANSEN et al., Immunogenics, (19800000), vol. 10, pages 247 - 260
    - ISHIDA et al., EMBO J, (19920000), vol. 11, pages 3887 - 95
    - FREEMAN et al., J Exp Med, (20000000), vol. 192, pages 1027 - 34
    - LATCHMAN et al., Nat Immunol, (20010000), vol. 2, pages 261 - 8
    - CARTER et al., Eur J Immunol, (20020000), vol. 32, pages 634 - 43
    - DONG et al., Nat. Med., (20020000), vol. 8, pages 787 - 9
    - DONG et al., J. Mol. Med., (20030000), vol. 81, pages 281 - 7
    - BLANK et al., Cancer Immunol. Immunother., (20050000), vol. 54, pages 307 - 314
    - KONISHI et al., Clin. Cancer Res., (20040000), vol. 10, pages 5094 - 100
    - IWAI et al., Proc. Natl. Acad. Sci. USA, (20020000), vol. 99, pages 12293 - 7
    - BROWN et al., J. Immunol., (20030000), vol. 170, pages 1257 - 66
    - NISHIMURA et al., Immunity, (19990000), vol. 11, pages 141 - 51
    - NISHIMURA et al., Science, (20010000), vol. 291, pages 319 - 22
    - SALAMA et al., J Exp Med, (20030000), vol. 198, pages 71 - 78
    - PROKUNIAALARCON-RIQUELME, Hum Mol Genet, (20040000), vol. 13, page R143
    - NIELSEN et al., Lupus, (20040000), vol. 13, page 510
    - OKAZAKI et al., PNAS, (20010000), vol. 98, pages 13866 - 71
    - Annu Rev Immunol, (20150000), vol. 33, pages 139 - 67
    - Stem Cells Transl Med, (20150100), vol. 4, no. 1, pages 66 - 73
    - Protein Engineering, (19960000), vol. 9, no. 3, pages 299 - 305
    - MARKS et al., J. Mol. Biol., (19910000), vol. 222, pages 581 - 597
    - N. Biotechnol., (20110000), vol. 28, no. 5, pages 253 - 457
    - "GenBank", Database accession no. AB009864
    - Mol Cell Biol, (19880000), vol. 8, pages 466 - 472
    - Expert Opin Investig Drugs, (20090700), vol. 18, no. 7, pages 991 - 1000
    - Curr Opin Immunol, (20160600), vol. 40, pages 96 - 102
    - Cancer Immunol Immunother, (20061200), vol. 55, no. 12, pages 1590 - 600
    - Immunology, (20110600), vol. 133, no. 2, pages 206 - 20
    - Nature Immunology, (20080000), vol. 9, pages 949 - 952
    - Nat Cell Biol, (20160100), vol. 18, no. 1, pages 43 - 53
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.